fda compounding glp-1 warning letters september 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines CDER Warning Letters Jump 50%
Description
Scott Harris, M.D., will be discussing the promise of #GLP1/#Glucagon approaches in treating #MASH and #MASLD, as well as the importance of developing therapies tailored to the specific needs of patients with #obesity and/or #MASH

Are GLP-1 meds like Ozempic affecting your PRP therapy results
You might wake up bloated,
Contains caffeine
Oncology dominates the hiring